Literature DB >> 16939748

Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis.

Scott D Grosse1, Margaret Rosenfeld, Owen J Devine, Huichuan J Lai, Philip M Farrell.   

Abstract

OBJECTIVE: To estimate the population impact of child mortality as a result of cystic fibrosis (CF) potentially preventable by newborn screening. STUDY
DESIGN: A systematic literature review of mortality in children with classic CF without meconium ileus (MI) in screened and unscreened cohorts was extended by contacting investigators for unpublished data. In addition, survival in US states with and without newborn screening (NBS) programs for CF was compared using data from the Cystic Fibrosis Foundation Patient Registry (CFFPR).
RESULTS: Among non-US studies, CF-related mortality risk to approximately 10 years of age was lower by 5 to 10 per 100 in screened cohorts. Unpublished US data from a trial of NBS for CF indicate no CF-related deaths to 10 years of age in either cohort. CFFPR data suggest improved survival among children with CF born in US states with NBS, with a CF-related mortality difference to 10 years of age between the screened and unscreened groups between 1.5 and 2 per 100 children with CF without MI.
CONCLUSION: In addition to improving nutritional outcomes, newborn screening for CF may result in improved child survival. The absolute differential in mortality risk, although modest in size, appears comparable to NBS for certain other genetic disorders.

Entities:  

Mesh:

Year:  2006        PMID: 16939748     DOI: 10.1016/j.jpeds.2006.04.059

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  30 in total

1.  A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.

Authors:  Janelle Wells; Marjorie Rosenberg; Gary Hoffman; Michael Anstead; Philip M Farrell
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

2.  Quantile regression for doubly censored data.

Authors:  Shuang Ji; Limin Peng; Yu Cheng; HuiChuan Lai
Journal:  Biometrics       Date:  2011-09-27       Impact factor: 2.571

3.  New challenges in the diagnosis and management of cystic fibrosis.

Authors:  Hara Levy; Philip M Farrell
Journal:  J Pediatr       Date:  2015-06       Impact factor: 4.406

Review 4.  Genetic screening.

Authors:  Wylie Burke; Beth Tarini; Nancy A Press; James P Evans
Journal:  Epidemiol Rev       Date:  2011-06-27       Impact factor: 6.222

Review 5.  Newborn screening: how are we travelling, and where should we be going?

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2011-04-16       Impact factor: 4.982

6.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

7.  The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.

Authors:  Scott D Grosse; John D Thompson; Yao Ding; Michael Glass
Journal:  Milbank Q       Date:  2016-06       Impact factor: 4.911

Review 8.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 10.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.